Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals

7

Late-breaking data from Phase 2 trial to UEG Week 2019, Barcelona, ​​Spain, potential highlights of investigation

Takeda acquires exclusive global license to investigational witch CNP-101 / TAK-101, the immune modifying nanoparticle t

OSAKA, Japan & CHICAGO – Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) and COUR Pharmaceutical Development Company, Inc. CNP-101 / TAK-101, the immune modifying nanoparticle containing gliadin proteins. Based on COURTs

Results of a randomized, double-blind, place-controlled abstraction and a late-breaking abstract at UEG Week 2019, Barcelona, Spain. For inclusion, patients with well-being biopsy proven celiac disease. After inclusion, they underwent the oral gluten challenge. Based on the study, Takeda exercised.

Asbest Parikh MD, Ph.D., Head, Gastroenterology Therapeutic Area Unit, Asit Parikh MD, Ph.D., Head, Gastroenterology Therapeutic Area Unit to Takeda. "Celiac disease." Celiac disease. Takeda is best positioned to develop the disease.

The gluten challenge per day for 3 days per day for 3 days. Spot forming units (SFUs) at a gluten-specific enzyme-linked immunospot (ELISpot) assay. This test is a direct measure of Gluten-Specific systemic T cell activation in celiac disease, and blocking this response Individuals with celiac disease suggests Could be protected from the effects of exposure Gluten. 31 patients were randomized and treated.

The primary endpoint of TAB-101 and placebo, respectively (p = 0.0056). 0.18 with TAK-101 compared with 0.63 with placebo (p = 0.079). The most frequent adverse events, headache, abdominal pain, and back pain. No patient has been diagnosed with chemotherapy, gluin-specific T cell proliferation and cytokine secretion.

Ed to initiateose init init ededededededededededededededededededededededededededededededededakakededededededededededed ed Yes, the best chance to get up to $ 420 million in future payments.

“We are a boss of the immune system,” said John J. Puzzle, CEO of COUR Pharmaceuticals. “As Takeda assumes responsibility for the celiac disease program, COUR will focus on advancing our pipeline of therapies from different sclerosis to allergy peanut.”

Tolerogenic immune reprogramming. Like celiac disease – like in celiac disease.

About Celiac Disease
Celiac disease is a genetically driven chronic immune-mediated disorder.1,2,3 Recent population-based studies in the U.S. celiac disease is around 1% t4 about 0.5% globally.5 The threshold of daily gluten tth of a slice of bread.6,7 Celiac disease, cause diarrhea, nausea, and vomiting. Long-term complications of celiac disease may include malnutrition, accelerated osteoporosis, nervous system problems and problems related to reproduction. The Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently Currently effective Currently effective Currently Currently Currently8

Takeda 's Commitment to Gastroenterology
Gastrointestinal (GI) diseases can be complex, debilitating, and life-changing. Recognizing this unmet need, Takeda and our partners. Takeda aspires to disease management. In addition, Takeda, such as inflammatory bowel disease. Our therapies and diseases are the best for scientific advancements through microbiome therapies.

About COUR Pharmaceuticals
COUR Pharmaceuticals is a first-in-class immune system. The effects of having toxic immune suppression. T Is the first demonstration of any disease. Data protection and inflammatory conditions. D. Guggenheim Research Professor of Microbiology – Immunology. T For more information, visit www.courpharma.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) is a global, values-based, headquartered leader in Japan. Takeda focus its R&D efforts on therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative solutions to create a robust, robust-diverse pipeline. 80 countries and regions.

For more information, visit https://www.takeda.com

Forward-Looking Statements
Takeda ttransportations and plans for Takeda. TArticle Directory: http: //www.articledashboard.com t Without limitation, “plans”, “plan”, “hopes”, “continues”, “expects”, “ends”, “Bòrd”, “ensures”, “will”. “,”, “Should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar negative expressions. Forfredi ya ya ya ya ya ya ya ya ya ya ya ya. Forward looking ed ed ed ed ed ed ed ed ed ak ed ed ed ak future ak ed and the United States; competitive pressure and developments; changes to applicable laws and regulations; the success of product development programs; decisions of the Commission; fluctuations in interest and currency exchange rates; claims or concerns; ; the companies; Takeda's actual results, performance, performance t achievements or financial common. t Takeda 's results, “Item 3. Key Information — D. Risk Factors ”in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, ed could from Should not rely on any forward-looking statements. Eda akes obligation release stock stock Past performance is not an indicator of Takeda's future results.

1 Jabri B, Sollid LM. T Cells in Celiac Disease. J Immunol 2017; 198: 3005-3014.
2 Molberg O, McAdam S, Lundin Ke, et al. T cells from celiac disease lesions with gluin epitopes in situ by endogenous tissue transglutaminase. Eur J Immunol 2001; 31: 1317-23.
3 Dieterich W, Ehnis T, Bauer M, et al. (C) the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
4 Leonard MM, Sapone A, Catassi C, et al. Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647-656.
5 Lionetti E, Gatti S, Pulvirenti A, et al. Celiac disease from a global perspective. Best Pract Res Clin Gastroenterial 2015; 29: 365-79.
6 Might gluten traces in celiac disease? A population-based probabilistic approach to risk estimation. About J Clin Nutr 2013; 97: 109-16.
7 Catassi C, Fabiani E, Iacono G, et al. Prospective, double-blind, place-controlled, celiac disease. About J Clin Nutr 2007; 85: 160-6.
8https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes (accessed October 9, 2019)

logo

Contacts

Takeda Pharmaceuticals
Media in Japan
Kazumi Kobayashi
+81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

U.S Media
Chris Stamm
+1 (617) 374-7726
chris.stamm@takeda.com

European Media
Luke Willats
+41 44-555-1145
luke.willats@takeda.com

COUR Pharmaceuticals
Canale Communications
Mari Purpura
+1 (619) 849-5384
mari@canalecomm.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.